ACADACADIA Pharmaceuticals Inc.

$19.78-19% 1Y

Is the business good?

Good

A genuinely good business: earnings fully cash-backed (2.4×), margins widening, and elite returns on assets.

3 good, 1 neutral
Fundamental health (F-score)5 / 9SEC EDGAR · Dec 31, 2025

Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.

Profits arrive as cash2.35×derived · Jun 30, 2026

Operating profit is fully backed by cash. Conversion is improving vs a year ago.

Margin direction, 3 years+32.6 pts

Operating profit is falling even as sales grow, costs are outrunning the top line.

Where ROE comes from22% ROA

High-quality, exceptional returns on the assets themselves, not leverage. ROE 30% = margin × turnover × leverage.

Unless marked, from derived.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversionbehind 85% of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is ACAD?

ACADIA Pharmaceuticals Inc. earns 19% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.

19%

Return on invested capital · cost of capital 9.0% · 10 points above what the capital costs: growth creates value

Operating margin
7.6%

Operating margin · Biotechnology median −77% · 12 months to Q2 2026

Cash conversion
2.35×

Cash conversion · 0.96× a year ago · operating cash flow covers the operating profit after tax

Share count, year on year
+2.5%

Share count, year on year · shareholders own a smaller slice than a year ago

Operating margin by fiscal year
YearOperating margin
FY2020−65%
FY2021−35%
FY2022−43%
FY2023−10%
FY202424%
FY20259.8%
Details›
Gross margin12 months to Q2 2026
91%
Operating margin12 months to Q2 2026
7.6%
Net margin12 months to Q2 2026
33%
Free cash flow margin
13%
R&D as % of revenue
29%
Revenue, trailing twelve months
$1.14B
Free cash flow, trailing twelve months
$146M
Net income, trailing twelve months
$380M
Return on invested capitaloperating profit after tax ÷ debt + equity − cash
19%

Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.